NCI-2022-07988

A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced Solid Tumors

This is an early-stage research study testing a new drug called YL201 in people with advanced solid tumors (cancers that have spread and are hard to treat). It’s a Phase 1 study, which means it's the first time YL201 is being tested in humans. The main goals are to find out if the drug is safe, what side effects it might cause, how the body absorbs and processes the drug (called pharmacokinetics), and whether it shows any early signs of working against cancer. The study is being done at multiple medical centers and is open-label, so patients and doctors know what treatment is being given.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05434234

Clinical Trial Site: Sinai

To see all available clinical trials click here.